# US 2017/0253594 A1 · Heteroaryl compounds for kinase inhibition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0253594 A1
- Document ID: US20170253594A1
- Status: Published application
- Kind: A1
- Application number: 15/600,023
- Filed: 2017-05-19
- Published: 2017-09-07
- Earliest claimed: 2014-06-19
- Assignees: ARIAD Pharmaceuticals, Inc.
- Applicants: Ariad Pharmaceuticals, Inc.
- Inventors: Wei-Sheng Huang; Yongjin Gong; Feng Li; Nicholas E. Bencivenga; David C. Delgamo; Anna Kohlmann; William C. Shakespeare; Ranny M. Thomas; Xiaotian Zhu; Angela V. West; Willmen Youngsaye; Yun Zhang; Tianjun Zhou
- Web page: https://patentgrep.com/patent/US20170253594A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/14: containing three or more hetero rings
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/14: containing three or more hetero rings
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07F 9/65583: {each of the hetero rings containing nitrogen as ring hetero atom}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.

## Claims

### Claim at position 1

-254. (canceled)

### Claim 255

A compound selected from:
or a pharmaceutically acceptable salt thereof.

### Claim 256 (depends on 255)

The compound or pharmaceutically acceptable salt of claim 255, which is

### Claim 257 (depends on 255)

The compound or pharmaceutically acceptable salt of claim 255, which is

### Claim 258 (depends on 255)

The compound or pharmaceutically acceptable salt of claim 255, which is

### Claim 259 (depends on 255)

The compound or pharmaceutically acceptable salt of claim 255, which is

### Claim 260 (depends on 255)

The compound or pharmaceutically acceptable salt of claim 255, which is

### Claim 261 (depends on 255)

The compound or pharmaceutically acceptable salt of claim 255, which is

### Claim 262 (depends on 255)

The compound or pharmaceutically acceptable salt of claim 255, which is

### Claim 263 (depends on 256)

A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 256, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 264 (depends on 257)

A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 257, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 265 (depends on 258)

A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 258, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 266 (depends on 259)

A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 259, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 267 (depends on 260)

A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 260, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 268 (depends on 261)

A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 261, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 269 (depends on 262)

A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 262, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
